MALAT1 is required for estradiol to act as a mitogen in hormone receptor-positive breast cancer

Breast cancer is not a single disease but a collection of different conditions, each driven by its own set of biological signals. About seven out of ten cases are what doctors call hormone receptor-positive, meaning the cancer cells have specific receptors on their surface that act like locks waiting for a key. The most common key for these tumors is a natural hormone called estrogen. When estrogen binds to these receptors, it tells the cancer cells to grow and divide, fueling the disease. For decades, the standard treatment has been to block this key or remove the locks, starving the cancer of its growth signal. However, many tumors eventually learn to resist these treatments, finding new ways to keep growing even when estrogen is blocked. This resistance is a major challenge, driving scientists to look deeper into the cell's internal machinery to find other ways to stop the cancer.

Inside every cell, there is a vast library of genetic instructions. While some of these instructions are written in the famous double-helix DNA that codes for proteins, a large portion consists of long strands of RNA that do not make proteins but instead act as regulators, turning other genes on or off. One of these regulatory strands, known as MALAT1, has been known for some time to be involved in cancer progression, but its exact role in hormone-driven breast cancer remained unclear. Researchers wanted to know if this specific RNA strand was essential for the cancer cells to respond to estrogen. If the cells could not grow without it, even when estrogen was present, then targeting MALAT1 might offer a new way to stop the cancer, especially in cases where current treatments fail.

A team of scientists set out to answer this question by working with two different types of breast cancer cells in the lab, as well as with fresh tissue samples taken directly from patients. They used a precise tool to silence the MALAT1 gene, effectively turning it off, and then watched what happened when they added estrogen back into the mix. In one type of cancer cell, known as MCF7, the results were striking. When the researchers removed MALAT1, the cells stopped growing entirely. Even when they added estrogen, which normally acts as a powerful growth signal, the cells did not respond. In fact, the combination of removing MALAT1 and adding estrogen made the cells grow even slower than when they were just deprived of the RNA. The cells began to show signs of stress and started to die off.

The story was slightly different in the second type of cancer cell, called T47D. In these cells, removing MALAT1 did not stop the cells from growing on its own, but it did weaken their response to estrogen. When estrogen was added, these cells still tried to grow, but they grew much more slowly than they would have if the MALAT1 RNA had been left alone. This difference between the two cell types showed that the role of MALAT1 is not the same in every cancer; it depends heavily on the specific environment and makeup of the cell. To make sure these findings were not just a laboratory artifact, the researchers tested the same approach on five different cultures of breast cancer cells grown from actual patient biopsies. In all five cases, removing MALAT1 stopped the cells from growing in response to estrogen, confirming that this mechanism works in real human tumors, not just in standard lab lines.

To understand why this was happening, the scientists looked inside the cells to see what changed when MALAT1 was removed. They found that the cells lost the ability to produce a specific enzyme called ME3, which helps protect the cell from oxidative stress and provides energy. At the same time, the cells started producing high levels of another enzyme called COX-2, which is usually associated with inflammation. When the researchers combined the removal of MALAT1 with the presence of estrogen, the levels of COX-2 spiked even higher. This surge in COX-2 activity, combined with the loss of the protective ME3 enzyme, seemed to push the cells into a state of stress that they could not survive. The estrogen, which usually tells the cell to multiply, instead triggered a chain reaction that led to cell death.

The researchers also discovered that removing MALAT1 changed how the cell's receptors behaved. In the cells that stopped growing, the estrogen receptors and the androgen receptors (which usually respond to male hormones) seemed to swap places on the DNA, binding to different spots than they normally would. This rearrangement appeared to confuse the cell's growth signals. When the scientists used a drug to block the androgen receptor, they could partially reverse the effects in some cells, suggesting that the androgen receptor played a role in this new, deadly response. However, this effect was not the same in all cells, reinforcing the idea that the cancer's response is highly specific to its internal chemistry.

The study concludes that MALAT1 is a critical piece of the puzzle that allows hormone-positive breast cancer to grow when stimulated by estrogen. Without it, the cancer cells lose their ability to translate the estrogen signal into growth, and in many cases, the signal instead triggers their own destruction. While the researchers did not test this as a treatment in people, their work identifies a new vulnerability in these tumors. It suggests that targeting MALAT1, perhaps in combination with existing hormone therapies, could be a way to stop the cancer from growing or even force it to die, particularly in cases where the cancer has become resistant to standard treatments. The findings also highlight that cancer cells are not uniform; what works in one type of cell might work differently in another, and understanding these subtle differences is key to developing better therapies.